NCT00715884Unknown不适用
A Prospective, Single-Blind, Randomized, Multi-Center Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems (ELITE).
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 678
- 试验地点
- 2
- 主要终点
- Percentage of Participants Who Experienced Target Lesion Failure (TLF)
研究概览
简要总结
The objective of this study is to show similar (non-inferior) safety and effectiveness between CYPHER® ELITE™ and CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems in a prospective, multi-center, randomized clinical study for the treatment of de novo native coronary lesions.
详细描述
A prospective, single-blind, randomized, multicenter, two arm study. The objective of this study is to show similar (non-inferior) safety and effectiveness between CYPHER® ELITE™ and CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems in a prospective, multi-center, randomized clinical study for the treatment of de novo native coronary lesions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with de novo atherosclerotic CAD in 1 or 2 vessels;
- •The subject must be >/= 18 years of age;
- •Female of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment;
- •Diagnosis of angina pectoris as defined by stable angina pectoris Canadian Cardiovascular Society Classification (Class I, II, III) OR non-ST segment elevation acute coronary syndrome (Braunwald Classification B&C) OR non-ST segment elevation myocardial infarction >/= 48 hours from the time of study index procedure OR asymptomatic subjects with a positive stress test;
- •Treatment of </= two lesions in one or two major coronary arteries (1 target lesion in each of 2 vessels or 2 target lesions in 1 vessel);
- •Target vessel diameter must be >/= 2.25mm and </= 4.0 in diameter (visual estimate);
- •Target lesion stenosis is > 50% and < 100% (visual estimate);
- •Target lesion length <30mm (for each target lesion(s)) with a total implanted stent length < 66mm. Additional stents can be used to treat dissections, etc,: however, these must be the same stent to which the subject has been randomized in the study.
- •Subject or Legally Authorized Representative must provide written informed consent prior to the procedure using a form that is approved by the Institutional Review Board/Independent Ethics Committee.
排除标准
- •ST Segment Elevation Myocardial Infarction (STEMI) within 30 days of the study index procedure;
- •Unprotected left main coronary disease with >/= 50% stenosis;
- •Total coronary occlusion or TIMI grade 0 or 1 in the target vessel;
- •Angiographic evidence of thrombus within target lesion(s);
- •Calcified target lesion(s) which cannot be, in the investigator's opinion, successfully pre-dilated;
- •Bifurcation disease involving a side branch >/= 2 mm in diameter;
- •Prior stent within 5 mm of target lesion(s);
- •Ostial target lesion(s);
- •Target lesion(s) within a coronary bypass graft (e.g., saphenous vein or arterial graft);
- •Documented left ventricular ejection fraction </= 25%;
- •Impaired renal function (creatinine > 250 μmol/L or > 2.5 mg/dl) at the time of treatment;
- •Pretreatment with devices other than conventional balloon angioplasty;
- •Significant angulation in the target vessel that, in the Investigator's opinion, may preclude stent delivery and deployment;
- •Subject previously treated with brachytherapy;
- •Recipient of heart transplant;
- •Subject with a life expectancy less than 12 months;
- •Known allergies to the following: aspirin, clopidogrel bisulfate and ticlopidine, heparin, stainless steel, contrast agent (that cannot be managed medically), or sirolimus that cannot be managed medically;
- •Any significant medical condition which, in the Investigator's opinion, may interfere with the subject's optimal participation in the study;
- •Currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the study endpoints;
- •In the Investigator's opinion, the lesion is not suitable for stenting;
- •Known bleeding or hypercoagulable disorder;
- •Known or suspected active infection at the time of the study procedures;
- •Subject is known to be pregnant, a prisoner, mentally incompetent, and/or alcohol or drug abuser;
- •Subject has had major surgical or interventional procedures unrelated to this study within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study.
结局指标
主要结局
Percentage of Participants Who Experienced Target Lesion Failure (TLF)
时间窗: 12-months post-procedure
The primary endpoint for this study is the percentage of participants who experienced Target Lesion Failure (TLF) during the 12 months post-procedure. A TLF event is defined as clinically-driven target lesion revascularization, target vessel myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 12 months post-procedure.
次要结局
- Percentage of Lesion Success(At procedure)
- Percentage of Device Success - Protocol Definition(At procedure)
- Percentage of Device Success - All CYPHER® Stents Included(At procedure)
- Percentage of Participants Who Achieved Procedure Success(At procedure during hospital stay)
- Percentage of Participants Who Experienced Target Lesion Revascularization (TLR)(12 months post-procedure)
- Percentage of Participants Who Experienced Target Vessel Revascularization (TVR)(12 months post procedure)
- Percentage of Participants Who Experienced Target Vessel Failure (TVF)(12 months post procedure)
- Percentage of Participants Who Experienced Major Adverse Cardiac Events (MACE)(12 months post procedure)
- Percentage of Participants Who Had Lesions of More Than 1 Vessel and Experienced Target Lesion Failure (TLF)(12 months post procedure)
- Percentage of Participants Who Had Diabetes and Experienced Target Lesion Failure (TLF)(12 months post procedure)
- Percentage of Participants Who Experienced Bleeding Complications(12 months post procedure)
- Percentage of Participants Who Died(12 months post procedure)
- Percentage of Participants Who Experienced Any Myocardial Infarction (MI)(12 months post procedure)
- Percentage of Participants Who Experienced Stroke(12 months post procedure)
- Percentage of Participants Who Experienced Stent Thrombosis (Protocol Definition)(12 months post procedure)
- Percentage of Participants Who Experienced Stent Thrombosis (Academic Research Consortium (ARC) Definition)(12 months post procedure)
- Percentage of Participants Who Experienced Early Stent Thrombosis (Academic Research Consortium (ARC) Definition)(0-30 days post-procedure)
- Percentage of Participants Who Experienced Late Stent Thrombosis (Academic Research Consortium (ARC) Definition)(31-360 days post-procedure)
研究者
研究点 (2)
Loading locations...
相似试验
终止
4 期
Intravenous (IV) Solutions for Dehydration in Children With GastroenteritisDehydrationGastroenteritisNCT01234883Baxter Healthcare Corporation100
撤回
不适用
Percutaneous Ultrasonic Tenotomy Versus Platelet Rich Plasma for Gluteal TendinopathyGluteal TendinitisTrochanteric BursitisTendinopathyNCT04299802Andrews Research & Education Foundation
已完成
3 期
A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic SuspensionOtitis ExternaNCT00980876Farmoquimica S.A.224
已完成
3 期
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and HumiraPlaque Type PsoriasisNCT02016105Sandoz465
已完成
1 期
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne VulgarisAcne VulgarisNCT01769664Taro Pharmaceuticals USA650